FDA Modernization Act

The 1938 Mandate

The original Federal Food, Drug, and Cosmetic Act of 1938 was itself a response to tragedy. The sulfanilamide disaster of 1937 — in which an untested toxic solvent in a liquid antibiotic killed 107 people, many of them children — prompted Congress to require that drugs be tested for safety before marketing.

For 84 years, this requirement was interpreted to mandate animal testing. No new drug could reach human clinical trials without first being tested in at least 2 animal species: 1 rodent and 1 non-rodent. The beagle became the standard non-rodent. The 1938 law did not name the beagle. It did not need to — regulatory custom and ICH guidelines filled in the specifics.

Modernization Act 2.0

The FDA Modernization Act 2.0 was signed into law on December 29, 2022. Its core provision is simple: it amended the Federal Food, Drug, and Cosmetic Act to state that drug sponsors may use "nonclinical tests or studies" — a term explicitly defined to include cell-based assays, organ chips, computer models, and other non-animal methods — instead of animal studies to support an investigational new drug application.

Key provisions:

• Removes the animal testing mandate — sponsors are no longer legally required to conduct animal studies. They may choose to do so, and many will, but the statutory obligation is gone.
• Does NOT ban animal testing — this distinction is critical. The law permits alternatives; it does not prohibit animal studies. Pharmaceutical companies remain free to test on beagles if they choose.
• Does NOT change FDA expectations — the FDA retains discretion to request animal data if it deems non-animal evidence insufficient. In practice, FDA reviewers accustomed to animal data continue to expect it.

Modernization Act 3.0

Version 3.0 passed the United States Senate unanimously in December 2025. It builds on 2.0 by:

• Directing FDA to develop guidance — requiring the agency to produce formal guidance documents specifying how non-animal methods can be used to satisfy regulatory requirements.
• Establishing timelines — setting deadlines for FDA to issue guidance and report on progress toward reducing animal testing.
• Expanding scope — addressing not just new drugs but also biologics, biosimilars, and certain device applications.

Unanimous Senate passage is rare and signals broad bipartisan support. However, passage through the House and presidential signature remain required for enactment. The legislative trajectory suggests eventual enactment, but the timeline is uncertain.

The FDA Phase-Out Plan

In April 2025, the FDA announced a concrete phase-out plan for certain animal testing requirements, starting with monoclonal antibodies (mAbs):

• Monoclonal antibodies first — mAbs are large-molecule biologics with well-understood mechanisms. The FDA determined that for many mAbs, animal toxicology studies provide limited predictive value because the drugs are human-specific — they often do not bind to the target in animal species.
• Phased approach — the plan envisions sequential reduction of animal testing requirements across drug classes, prioritizing those where non-animal alternatives are most mature.
• Not immediate — the phase-out plan sets directions, not deadlines. Individual drug applications will be evaluated on a case-by-case basis.

Why Practical Impact Is Slow

The gap between legal permission and practical change is wide. Several factors slow the transition:

• Regulatory conservatism — FDA reviewers evaluate drugs based on safety. The burden of proof for any change falls on the sponsor. Demonstrating that a non-animal method is "adequate and well-controlled" requires validation data that is still being generated for most alternative methods.
• ICH guidelines — the International Council for Harmonisation guidelines (M3, S7A, S7B, S9) are adopted by the US, EU, and Japan. These guidelines specify animal studies. Changing them requires international consensus, which moves slowly.
• Industry inertia — pharmaceutical companies have established workflows, CRO contracts, and internal expertise built around animal testing. Switching to unfamiliar methods introduces uncertainty and perceived risk.
• Liability calculus — if a drug harms patients after being approved based on non-animal data, the sponsor faces potential litigation. The legal and reputational risk of being first to abandon animal testing discourages early movers.
• Cardiovascular safety — despite its documented limitations, dog telemetry data remains expected for most small-molecule drugs. The CiPA initiative offers a potential replacement, but full regulatory acceptance is years away.

What This Means for Beagles

The FDA Modernization Act is the most significant legislative development for laboratory beagles in decades. It removes the legal floor that required their use. But removing a floor is not the same as changing practice.

For the foreseeable future, the majority of new drug applications will continue to include beagle toxicology data. The drugs that reach the market in the late 2020s and 2030s will, overwhelmingly, have been tested on dogs. The Modernization Act creates the possibility of a different future. It does not guarantee one.

Sources

1. 1.FDA Modernization Act 2.0, 2022. Public Law 117-328, Section 3209. Amends the Federal Food, Drug, and Cosmetic Act to permit non-animal testing methods for drug development.
2. 2.FDA Modernization Act 3.0, 2025. Senate-passed legislation directing FDA guidance development and establishing timelines for non-animal method adoption.
3. 3.Preclinical Rationale, 2024. Analysis of the scientific and regulatory basis for animal testing requirements and the evidentiary standards for alternative methods.
4. 4.FDA Phase-Out Plan, April 2025. FDA announcement of phased reduction of animal testing requirements beginning with monoclonal antibodies.